Although some studies demonstrated that intravitreal anti-VEGF agents did not increase the risks of ATEs comparing to the non-IVI groups, patients with cardiovascular diseases, or patients with an AMI/IS history were excluded in those studies41,42, which the included cases were less than those in real world situation. The gene discussed is VEGFA; the disease is cardiovascular disorder.